Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
{{custom_author.name}}, {{article.zuoZheEn}}
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
[{{custom_ref.label}}] |
{{custom_citation.content}}
|
/
〈 | 〉 |